Order Article Reprints

Schreiber AR, Kagihara JA, Corr BR, Davis SL, Lieu C, Kim SS, Jimeno A, Camidge DR, Williams J, Heim AM, et al. First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors. Cancers. 2024; 16(1):91. https://doi.org/10.3390/cancers16010091

Schreiber, Anna R., Jodi A. Kagihara, Bradley R. Corr, S. Lindsey Davis, Christopher Lieu, Sunnie S. Kim, Antonio Jimeno, D. Ross Camidge, Jud Williams, Amy M. Heim, and et al. 2024. "First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors" Cancers 16, no. 1: 91. https://doi.org/10.3390/cancers16010091

Schreiber, A. R., Kagihara, J. A., Corr, B. R., Davis, S. L., Lieu, C., Kim, S. S., Jimeno, A., Camidge, D. R., Williams, J., Heim, A. M., Martin, A., DeMattei, J. A., Holay, N., Triplett, T. A., Eckhardt, S. G., Litwiler, K., Winkler, J., Piscopio, A. D., & Diamond, J. R. (2024). First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors. Cancers, 16(1), 91. https://doi.org/10.3390/cancers16010091